High expression of muscarinic acetylcholine receptor 3 predicts poor prognosis in patients with pancreatic ductal adenocarcinoma
Authors Zhang L, Xiu DR, Zhan J, He XK, Guo LM, Wang JL, Tao M, Fu W, Zhang HQ
Received 26 April 2016
Accepted for publication 9 September 2016
Published 31 October 2016 Volume 2016:9 Pages 6719—6726
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Jia Fan
Peer reviewer comments 3
Editor who approved publication: Professor Jianmin Xu
Lingfu Zhang,1 Dianrong Xiu,1 Jun Zhan,2,3 Xiaokun He,3 Limei Guo,4,5 Jilian Wang,1 Ming Tao,1 Wei Fu,1 Hongquan Zhang2,3
1Department of General Surgery, Peking University Third Hospital, 2Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, State Key Laboratory of Natural and Biomimetic Drugs, 3Laboratory of Molecular Cell Biology and Tumor Biology, Department of Anatomy, Histology and Embryology, 4Department of Pathology, Peking University Health Science Center, 5Department of Pathology, Peking University Third Hospital, Beijing, People’s Republic of China
Aims: Recent studies showed that muscarinic acetylcholine receptor 3 (M3), as a muscarinic acetylcholine receptor family member that plays an important role in normal physiological function, is engaged in cancer progression. However, the role of M3 in pancreatic ductal adenocarcinoma (PDAC) is not known. The aim of this study is to investigate the expression and prognostic value of M3 in patients with PDAC.
Materials and methods: The localization and expression of M3 in PDAC were examined by immunohistochemistry. VAChT was employed to detect parasympathetic nerve fibers in the corresponding M3 PDAC tissues. The correlation between M3 expression and patients’ survival was assessed by Kaplan–Meier analysis.
Results: M3 was discovered predominantly localized in the cell cytoplasm and expressed in all specimens of PDAC patients. Significant correlation was noted between increased M3 intensity and high grade of PDAC (P<0.01), more lymph node metastasis (P<0.01) as well as shorter patient overall survival (P<0.01). Morphologically, cells with high M3 expression were more frequently located at the invasive tumor front/tumor budding cells, metastatic lymph nodes and parasympathetic nerve fibers.
Conclusion: High expression of M3 is a prognostic marker for PDAC.
Keywords: PDAC, muscarinic acetylcholine receptor 3, M3, tumor budding, parasympathetic nerve fiber, prognosis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]